Incidence, risk factors of injection site reactions with degarelix investigated
the ONA take:
In a recent study, investigators sought to determine the incidence of injection site reactions (ISRs) after administration of degarelix as well as identify the risk factors for ISRs.
The study involved 50 men receiving subcutaneous therapy for the first time. The men received 240 mg degarelix, administered as two 3-mL subcutaneous injections.
Mean age of patients was 75.6 years, and mean prostate-specific antigen (PSA) level just before degarelix administration was 198.4 ng/mL.
Thirty-three patients received hormonal therapy with degarelix for the first time; 11 patients were receiving an oral steroid (six for prostate cancer, one for hematologic disease, and four for allergic conditions).
Injection site reactions were observed in 25 patients, all categorized as grade 1 or 2. Two patients discontinued digarelix due to ISR. Study findings showed incidence of ISRs in patients receiving subcutaneous therapy for the first time was 64%; incidence of ISRs in patients also receiving an oral steroid was 18%.
The investigators recommend patient education include information on the possibility of ISR due to degarelix prior to administration, especially patients who are not receiving steroids and those who have no experience with subcutaneous injections.
Investigators sought to determine the incidence of injection site reactions after administration of degarelix.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|